anticoagulant
DESCRIPTION
ANTICOAGULANT. BY :DR ISRAA OMAR. Definition of Anticoagulation. Therapeutic interference ("blood-thinning") with the clotting mechanism of the blood to prevent or treat thrombosis and embolism. Indications of Anticoagulant Therapy. Treatment and Prevention of Deep Venous Thrombosis - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/1.jpg)
ANTICOAGULANT
BY :DR ISRAA OMAR
![Page 2: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/2.jpg)
Definition of Anticoagulation
• Therapeutic interference ("blood-thinning") with the clotting mechanism of the blood to prevent or treat thrombosis and embolism.
![Page 3: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/3.jpg)
Indications of Anticoagulant Therapy
• Treatment and Prevention of Deep Venous Thrombosis
• Pulmonary Emboli• Prevention of stroke in patients with atrial fibrillation,
artificial heart valves, cardiac thrombus.• During procedures such as cardiac catheterisation
![Page 4: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/4.jpg)
Enhances Antithrombin Activity
![Page 5: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/5.jpg)
Standard Heparin• Heterogeneous mixture of polysaccharide chains• MW 3k to 30k • Active in vitro and in vivo• Administration - parenteral- Do not inject IM - only IV
or deep s.c. • Half-life 1 - 2 hrs - monitor APTT• Adverse effect - haemorrhage – • antidote - protamine sulphate
![Page 6: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/6.jpg)
Heparin mechanism of action
Heparin
Antithrombin III Thrombin
![Page 7: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/7.jpg)
Monitoring Heparin
• Activated Partial Thromboplastin Time (APTT)• Normal range: 25-40 seconds • Therapeutic Range: 55-70 seconds
![Page 8: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/8.jpg)
Low Molecular Weight Heparin
• Changed management of venous thromboembolism
• Standard (Unfractionated) heparin 30k• LMWH contains polysaccharide chains MW 5k• Enriched with short chains with higher anti-
Xa:IIa ratio
![Page 9: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/9.jpg)
Differences in Mechanism of Action
• Any size of heparin chain can inhibit the action of factor Xa by binding to antithrombin (AT)
• In contrast, in order to inactivate thrombin (IIa), the heparin molecule must be long enough to bind both antithrombin and thrombin
• the chains of LMWH are not long enough to bind antithrombin and thrombin
![Page 10: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/10.jpg)
![Page 11: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/11.jpg)
![Page 12: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/12.jpg)
![Page 13: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/13.jpg)
Complications of Heparin
• Hemorrhage(can be reversed by using protamine sulfate as an antidote)
• Heparin-induced thrombocytopenia (HIT) and thrombosis
• Osteoporosis (long-term only)more than 6 month ;the explanation of this side effect is unknown
• Hyperkalemia • Hypersensitivity reaction
![Page 14: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/14.jpg)
Heparin-Induced Thrombocytopaenia
• Most significant adverse effect of heparin after haemorrhage
• Most common drug-induced thrombocytopenia
![Page 15: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/15.jpg)
Trreatment of HIT
• Discontinue all heparin• If need to continue anti-coagulation, use
danaparoid (orgaran).• Avoid platelet transfusions• Thrombosis: use danaparoid or thrombin
inhibitor(Hirudin)
![Page 16: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/16.jpg)
Oral anticoagulant • Warfarin is an oral anticoagulant that prevent
thrombosis• It inhibit the enzymatic reduction of vitamin K
to its hydroquinone form, interfering with the post transtional modification (carboxylation) of glutamic acid residues in clotting factors 2, 9, 7, 10.
• Warfarin acts only in vivo
![Page 17: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/17.jpg)
Vitamin K
Synthesis of Functional
Coagulation Factors
VII
IX
X
II
Vitamin K-Dependent Clotting Factors
![Page 18: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/18.jpg)
Warfarin
Synthesis of Non Functional
Coagulation Factors
Antagonismof
Vitamin K
Warfarin Mechanism of Action
Vitamin K
VII
IX
X
II
![Page 19: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/19.jpg)
Warfarin
![Page 20: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/20.jpg)
Side effects of warfarin • Bleeding• Hepatotoxicity • Warfarin induced skin necrosis(can be reduced
by starting heparin and warfarin concomitantly)
![Page 21: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/21.jpg)
Warfarin: Major Adverse Effect—Haemorrhage
• Factors that may influence bleeding risk:– Intensity of anticoagulation– Concomitant clinical disorders(liver disease ,thyrotoxicosis and fever )– Concomitant use of other medications1. Cimetidine and other enzyme inhibitors increase its action while
rifampicin and other enzyme inducers inhibit the action of warfarin 2. aspirin increase its bleeding risk by working in synergistic
fashion(PLATELETS INHIBITION) .3. NSAIDS and chloral hydrate displace it from binding sites4. Antibiotic eliminate the intestinal flora that produce vitamin k this
will increase the risk of bleeding – Quality of management
![Page 22: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/22.jpg)
Prothrombin Time (PT)• Historically, a most reliable and “relied upon” clinical
testHowever:
– Proliferation of thromboplastin reagents with widely varying sensitivities to reduced levels of vitamin K-dependent clotting factors has occurred
– Problem addressed by use of INR (International Normalized Ratio)
![Page 23: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/23.jpg)
Changing over from Heparin to Warfarin
• May begin concomitantly with heparin therapy• Heparin should be continued for a minimum of four
days– Time to peak antithrombotic effect of warfarin is
delayed 96 hours (despite INR)• When INR reaches desired therapeutic range,
discontinue heparin (after a minimum of four days)
![Page 24: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/24.jpg)
Warfarin: Dosing & Monitoring• Start low
– Initiate 5 mg daily– Educate patient
• Stabilize– Titrate to appropriate INR – Monitor INR frequently (daily then weekly)
• Adjust as necessary• Monitor INR regularly (every 1–4 weeks) and adjust
![Page 25: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/25.jpg)
Contraindications to Warfarin Therapy
• Pregnancy (it is a erotogenic drug can cause maxillofacial abnormality if given in the first trimester and increase the incidence of bleeding in the new born baby in the last trimester ;but it can be given in the middle trimester of pregnancy but with higher doses to achieve the target INR because there is hyper-coaguability state during pregnancy
• Situations where the risk of hemorrhage is greater than the potential clinical benefits of therapy– Uncontrolled alcohol/drug abuse– Unsupervised dementia/psychosis
![Page 26: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/26.jpg)
Signs of Warfarin Overdosage
• Any unusual bleeding:– Blood in stools or urine– Excessive menstrual bleeding– Bruising– Excessive nose bleeds/bleeding gums– Persistent oozing from superficial injuries– Bleeding from tumor, ulcer, or other lesion
![Page 27: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/27.jpg)
Reversing action of warfarin
• Plasma(fresh frozen plasma or clotting factors)– Rapid but short-lasting, used mainly for life
threating bleeding • Vitamin K
– Not rapid, but lasts 1-2 weeks. Do not use if wishing to restart warfarin within next week.
In some cases only stopping the drug can be enough
![Page 28: ANTICOAGULANT](https://reader034.vdocuments.site/reader034/viewer/2022051821/568160c9550346895dcffa85/html5/thumbnails/28.jpg)
Thank you